SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Balchem Corp. – ‘8-K’ for 3/25/24

On:  Friday, 3/29/24, at 4:15pm ET   ·   For:  3/25/24   ·   Accession #:  1140361-24-16602   ·   File #:  1-13648

Previous ‘8-K’:  ‘8-K’ on / for 2/16/24   ·   Latest ‘8-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/29/24  Balchem Corp.                     8-K:5,7,9   3/25/24   10:153K                                   Broadridge Fin’l So… Inc

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 5: R1          Document and Entity Information                     HTML     45K 
 7: XML         IDEA XML File -- Filing Summary                      XML     12K 
10: XML         XBRL Instance -- ef20025497_8k_htm                   XML     14K 
 6: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- bcpc-20240325_lab                     XML     63K 
 4: EX-101.PRE  XBRL Presentations -- bcpc-20240325_pre              XML     45K 
 2: EX-101.SCH  XBRL Schema -- bcpc-20240325                         XSD     14K 
 8: JSON        XBRL Instance as JSON Data -- MetaLinks               13±    20K 
 9: ZIP         XBRL Zipped Folder -- 0001140361-24-016602-xbrl      Zip     14K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 
 i false i 0000009326 i NASDAQ00000093262024-03-252024-03-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM  i 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i March 25, 2024

 i Balchem Corporation
(Exact name of registrant as specified in its charter)

 i Maryland
 i 1-13648
 i 13-2578432
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

 i 5 Paragon Drive,  i Montvale,  i NJ  i 07645
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: ( i 845)  i 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 i 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


 i 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 i Common Stock, par value $.06-2/3 per share
 i BCPC
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 
Emerging growth company
 i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 27, 2024, Balchem Corporation (the “Company”) announced that Jonathan H. Griffin, Senior Vice President and General Manager, Animal Nutrition and Health, would be moving into the role of Senior Vice President, Corporate Development, effective immediately. In this new role, Mr. Griffin will partner with the business segment and functional leaders in evaluating and managing business opportunities, including potential acquisitions, mergers, joint ventures, and partnerships. There are no material changes to Mr. Griffin’s compensatory arrangement as a result of this change.

Item 7.01
Regulation FD Disclosure.

On March 27, 2024, the Company also announced that C. Martin Bengtsson, Executive Vice President and Chief Financial Officer, would be expanding his responsibilities to include leadership of the Animal Nutrition and Health segment, effective immediately.  There are no material changes to Mr. Bengtsson’s compensatory arrangement as a result of his expanded responsibilities.

Item 9.01
Financial Statements and Exhibits.

(d)  Exhibits

Exhibit Number
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BALCHEM CORPORATION
 
(Registrant)
   
 
By:
 
 
 
Executive Vice President, General Counsel and Secretary
   
 




Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:3/29/24None on these Dates
3/27/24
For Period end:3/25/24
 List all Filings 
Top
Filing Submission 0001140361-24-016602   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 12:31:54.1pm ET